{"title":"心脏康复运动加沙比利缬沙坦钠对慢性心力衰竭患者心功能、肺功能和生活质量的影响","authors":"Xiaoqi Li, Ping Zhang, Jinlun Cai, Liu Shi, Qiaoyan Ma, Zhongwen Xue","doi":"10.14744/AnatolJCardiol.2025.5434","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To explore the impacts of cardiac rehabilitation exercise plus sacubitril valsartan sodium on cardiac function, lung function, and quality of life in chronic heart failure (CHF) patients.</p><p><strong>Methods: </strong>One hundred and forty-six CHF patients admitted to the hospital from January 2023 to December 2024 were chosen and divided into a control group (conventional treatment + sacubitril valsartan sodium) and a study group (conventional treatment + sacubitril valsartan sodium + cardiac rehabilitation exercise).</p><p><strong>Results: </strong>The total effective rate of the study group was higher when comparing with the control group (P < .05). The study group had higher left ventricular ejection fraction level as well as lower left ventricular end-systolic diameter, left ventricular end-diastolic diameter, and N-terminal pro B-type natriuretic peptide levels when comparing with the control group after 3 months of intervention (P < .01). The study group had higher forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC levels when comparing with the control group following 3 months of intervention (P < .01). The study group had higher SpO2, PaO2, and PaO2/FiO2 levels after 3 months of intervention (P < .01). The study group had longer 6-minute walking test after 3 months of intervention (P < .01). The study group had lower MLHFQ score when comparing with the control group after 3 months of intervention (P < .01). The rate of rehospitalization and incidence of major adverse cardiovascular event (MACE) in the study group were lower than in the control group (P < .05).</p><p><strong>Conclusion: </strong>Cardiac rehabilitation exercise combined with sacubitril valsartan sodium is effective in treating CHF patients, which improves cardiac function, lung function and blood gas levels, promotes exercise endurance and quality of life, and reduces the rehospitalization rate and MACE incidence in CHF patients.</p>","PeriodicalId":7835,"journal":{"name":"Anatolian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of Cardiac Rehabilitation Exercise Plus Sacubitril Valsartan Sodium on Cardiac Function, Lung Function, and Quality of Life in Patients with Chronic Heart Failure.\",\"authors\":\"Xiaoqi Li, Ping Zhang, Jinlun Cai, Liu Shi, Qiaoyan Ma, Zhongwen Xue\",\"doi\":\"10.14744/AnatolJCardiol.2025.5434\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>To explore the impacts of cardiac rehabilitation exercise plus sacubitril valsartan sodium on cardiac function, lung function, and quality of life in chronic heart failure (CHF) patients.</p><p><strong>Methods: </strong>One hundred and forty-six CHF patients admitted to the hospital from January 2023 to December 2024 were chosen and divided into a control group (conventional treatment + sacubitril valsartan sodium) and a study group (conventional treatment + sacubitril valsartan sodium + cardiac rehabilitation exercise).</p><p><strong>Results: </strong>The total effective rate of the study group was higher when comparing with the control group (P < .05). The study group had higher left ventricular ejection fraction level as well as lower left ventricular end-systolic diameter, left ventricular end-diastolic diameter, and N-terminal pro B-type natriuretic peptide levels when comparing with the control group after 3 months of intervention (P < .01). The study group had higher forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC levels when comparing with the control group following 3 months of intervention (P < .01). The study group had higher SpO2, PaO2, and PaO2/FiO2 levels after 3 months of intervention (P < .01). The study group had longer 6-minute walking test after 3 months of intervention (P < .01). The study group had lower MLHFQ score when comparing with the control group after 3 months of intervention (P < .01). The rate of rehospitalization and incidence of major adverse cardiovascular event (MACE) in the study group were lower than in the control group (P < .05).</p><p><strong>Conclusion: </strong>Cardiac rehabilitation exercise combined with sacubitril valsartan sodium is effective in treating CHF patients, which improves cardiac function, lung function and blood gas levels, promotes exercise endurance and quality of life, and reduces the rehospitalization rate and MACE incidence in CHF patients.</p>\",\"PeriodicalId\":7835,\"journal\":{\"name\":\"Anatolian Journal of Cardiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anatolian Journal of Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.14744/AnatolJCardiol.2025.5434\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anatolian Journal of Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14744/AnatolJCardiol.2025.5434","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Effects of Cardiac Rehabilitation Exercise Plus Sacubitril Valsartan Sodium on Cardiac Function, Lung Function, and Quality of Life in Patients with Chronic Heart Failure.
Background: To explore the impacts of cardiac rehabilitation exercise plus sacubitril valsartan sodium on cardiac function, lung function, and quality of life in chronic heart failure (CHF) patients.
Methods: One hundred and forty-six CHF patients admitted to the hospital from January 2023 to December 2024 were chosen and divided into a control group (conventional treatment + sacubitril valsartan sodium) and a study group (conventional treatment + sacubitril valsartan sodium + cardiac rehabilitation exercise).
Results: The total effective rate of the study group was higher when comparing with the control group (P < .05). The study group had higher left ventricular ejection fraction level as well as lower left ventricular end-systolic diameter, left ventricular end-diastolic diameter, and N-terminal pro B-type natriuretic peptide levels when comparing with the control group after 3 months of intervention (P < .01). The study group had higher forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC levels when comparing with the control group following 3 months of intervention (P < .01). The study group had higher SpO2, PaO2, and PaO2/FiO2 levels after 3 months of intervention (P < .01). The study group had longer 6-minute walking test after 3 months of intervention (P < .01). The study group had lower MLHFQ score when comparing with the control group after 3 months of intervention (P < .01). The rate of rehospitalization and incidence of major adverse cardiovascular event (MACE) in the study group were lower than in the control group (P < .05).
Conclusion: Cardiac rehabilitation exercise combined with sacubitril valsartan sodium is effective in treating CHF patients, which improves cardiac function, lung function and blood gas levels, promotes exercise endurance and quality of life, and reduces the rehospitalization rate and MACE incidence in CHF patients.
期刊介绍:
The Anatolian Journal of Cardiology is an international monthly periodical on cardiology published on independent, unbiased, double-blinded and peer-review principles. The journal’s publication language is English.
The Anatolian Journal of Cardiology aims to publish qualified and original clinical, experimental and basic research on cardiology at the international level. The journal’s scope also covers editorial comments, reviews of innovations in medical education and practice, case reports, original images, scientific letters, educational articles, letters to the editor, articles on publication ethics, diagnostic puzzles, and issues in social cardiology.
The target readership includes academic members, specialists, residents, and general practitioners working in the fields of adult cardiology, pediatric cardiology, cardiovascular surgery and internal medicine.